Effectiveness of an Immediate Mitomycin C Instillation in Patients with Superficial Bladder Cancer Receiving Periodic Mitomycin C Instillation.
10.4111/kju.2011.52.5.323
- Author:
Seok Jin JUNG
1
;
Hyuk Soo CHANG
;
Choal Hee PARK
;
Chun Il KIM
;
Byung Hoon KIM
Author Information
1. Department of Urology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. blackporori@dsmc.or.kr
- Publication Type:Original Article
- Keywords:
Intravesical instillation;
Mitomycin;
Urinary bladder neoplasms
- MeSH:
Administration, Intravesical;
Follow-Up Studies;
Humans;
Mitomycin;
Recurrence;
Retrospective Studies;
Urinary Bladder;
Urinary Bladder Neoplasms
- From:Korean Journal of Urology
2011;52(5):323-326
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We analyzed the impact of immediate intravesical mitomycin C instillation after transurethral resection of the bladder (TURB) on tumor recurrence and progression in patients with periodic mitomycin C instillation. MATERIALS AND METHODS: Between June 2000 and June 2006, a retrospective study was performed in a total of 115 patients with primary bladder tumors receiving a 6-week course of mitomycin C instillation after TURB. The patients were assigned to two groups: 53 patients in the immediate mitomycin C (I-MMC) group were treated by immediate instillation of mitomycin C after TURB and periodic instillation (6 times, 1 time per week), and 62 patients in the MMC group received only periodic instillation. Tumor recurrence and progression were compared in the two groups. RESULTS: During the mean follow-up period of 46.5 months in the I-MMC group and 47.2 months in the MMC group, early recurrence (within 1 year) occurred in 6 of 53 patients (11.3%) in the I-MMC group and in 18 of 62 patients (29.0%) in the MMC group (p<0.02). Although a significantly lower early recurrence rate was observed in the I-MMC group, this difference was not significant for recurrence within 2 or 3 years or for total recurrence. Progression was not significantly different between the two groups regarding the early and total period. CONCLUSIONS: Our study confirmed the positive effect of a single, immediate mitomycin C instillation in patients with non-muscle-invasive bladder tumors who received periodic mitomycin C instillation. This benefit was limited to early recurrence and was not maintained with long-term follow-up. This approach can be an alternative to periodic mitomycin C instillation without immediate instillation.
